RIVER EDGE, N.J.—Medical device company Nephros Inc. reported March 24 that is has entered into a development agreement with STERIS Corp. to develop filtration-based products for medical device applications.
Under the terms of the agreement, Nephros received an initial payment upon entering into the agreement and is eligible to receive additional payments upon successful completion of product development milestones.
Financial details of the agreement were not disclosed.
In 2009, Nephros received 510(k) marketing approval from the FDA for the Dual-Stage Ultrafilter (DSU) to be used to filter biological contaminants from water and bicarbonate concentrate used in hemodialysis procedures.
In August 2009, Nephros reported that it was awarded a new research contract from the U.S. Office of Naval Research for development of a portable dual-stage purifying filter.
"Nephros is investigating a range of commercial, industrial and retail opportunities for its DSU technology," said Ernest Elgin, president and CEO of Nephros. "We are pleased to be working with STERIS to leverage our expertise in additional applications. STERIS is a leader in the field of medical device sterilization, and we look forward to developing new products together to enhance patient safety."
